Is dapagliflozin only for diabetes?

No. Dapagliflozin (Farxiga) has FDA approval for type 2 diabetes, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and chronic kidney disease (with or without diabetes). It is one of the first medications with such broad cardiovascular and renal indications.

What is the sick-day rule for dapagliflozin?

During illness (especially with vomiting, diarrhea, or significantly reduced food/fluid intake), stop dapagliflozin and contact your prescriber. Dehydration combined with SGLT2 inhibition can increase DKA and kidney injury risk. Resume when you are eating and drinking normally and your provider has confirmed it is safe.

Will dapagliflozin cause low blood sugar?

On its own, dapagliflozin has low hypoglycemia risk. When combined with insulin or sulfonylureas, hypoglycemia risk increases and dose adjustments of the insulin or sulfonylurea may be needed when starting dapagliflozin.

Why is there a small eGFR drop when I start dapagliflozin?

A small transient reduction in eGFR (kidney filtration rate) is expected within the first few weeks of SGLT2 inhibitor therapy. This reflects a beneficial reduction in intraglomerular pressure, not kidney damage. The eGFR typically stabilizes and the long-term kidney-protective effect is well established.

What to Expect When Starting Dapagliflozin

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Dapagliflozin (Farxiga) is an SGLT2 inhibitor used to treat type 2 diabetes, reduce hospitalizations for heart failure (both reduced and preserved ejection fraction), and slow chronic kidney disease progression — making it one of the most broadly indicated medications in its class. It lowers blood sugar by causing the kidneys to excrete glucose in the urine and offers significant cardiovascular and kidney protective benefits beyond glycemic control.

Week-by-week timeline

Day 1-3

Initial Effects

Blood glucose begins to lower within the first day as urinary glucose excretion increases. Increased urination and mild thirst are expected. Genital hygiene is important to reduce yeast infection risk. Monitor blood pressure, as modest reductions occur quickly.

Week 1-2

Adjustment and Monitoring

Increased urination typically stabilizes by week 2. Watch for genital yeast infections (itching, discharge, odor) — more common in women and uncircumcised men. UTI risk is modestly elevated. Maintain good hydration.

Week 2-4

Metabolic Benefits

For diabetes: HbA1c reductions of 0.5-1% become measurable over weeks to months. For heart failure (regardless of diabetes): benefit begins within the first month. Weight may decrease modestly due to caloric loss and modest diuretic effect.

Month 1

Lab and Clinical Monitoring

Kidney function (eGFR, creatinine), electrolytes, and blood pressure should be checked. A transient decrease in eGFR is expected at initiation and does not mean kidney damage — it reflects altered kidney filtration pressure. Dapagliflozin is not recommended if eGFR is below 25 mL/min for diabetes, though it can be used for heart failure/CKD down to eGFR 25.

Month 2-3

Long-Term Benefits Accumulate

Major trials (DAPA-HF, DAPA-CKD, DECLARE-TIMI) demonstrate reduced cardiovascular events, hospitalization for heart failure, kidney disease progression, and all-cause mortality with long-term dapagliflozin use. These benefits accrue over months to years.

When to call your doctor

Contact your healthcare provider if you experience:

Signs of diabetic ketoacidosis (DKA): nausea, vomiting, abdominal pain, fatigue, shortness of breath, fruity breath — even with normal or near-normal blood sugar (euglycemic DKA)
Signs of Fournier gangrene: pain, redness, or swelling in the genital or perineal area with fever (rare but serious — seek emergency care)
Significant decrease in urination, rapid weight gain, or swelling (kidney problems or heart failure worsening)
Signs of low blood sugar if combined with insulin or sulfonylureas
Recurrent genital infections that do not respond to treatment
Severe urinary tract infection: fever, back pain, chills, nausea

Tips for getting started

Take dapagliflozin once daily in the morning, with or without food. Before any surgical procedure or prolonged fasting, hold dapagliflozin for at least 3 days (longer for major surgery) to reduce DKA risk — always inform your surgical team. Maintain good genital hygiene. If you develop a genital yeast infection, over-the-counter antifungals are effective — inform your doctor. Stay hydrated, especially during hot weather or illness. If you are sick with reduced oral intake, hold dapagliflozin and contact your prescriber.

Frequently asked questions

More about Dapagliflozin

Dapagliflozin drug guideSide effects, dosage, interactions, and more Canagliflozin vs DapagliflozinCompare these medications Empagliflozin vs DapagliflozinCompare these medications Dapagliflozin vs EmpagliflozinCompare these medications Dapagliflozin & MetforminInteraction details Dapagliflozin & Insulin glargineInteraction details

References

[Regulatory] FDA Label: Farxiga (dapagliflozin) Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202293s030lbl.pdf Accessed 2026-03-01.
[Regulatory] NIH MedlinePlus: Dapagliflozin https://medlineplus.gov/druginfo/meds/a614011.html Accessed 2026-03-01.
[Clinical] DAPA-HF Trial: Dapagliflozin and Heart Failure https://www.nejm.org/doi/10.1056/NEJMoa1911303 Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026